TuHURA Biosciences, Inc. (HURA) Stock Score, Valuation & Financial Research

TuHURA Biosciences, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for HURA

TuHURA Biosciences, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.10. These figures are a research snapshot, not a buy or sell recommendation.

What TuHURA Biosciences, Inc. does

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

TuHURA Biosciences is a clinical-stage immuno-oncology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity and debt financing to fund the research, development, and clinical trial testing of its proprietary cancer vaccine and immunotherapy product candidates.

Products and services

  • The company is developing IFx-2.0, an innate immune response agonist candidate for Merkel Cell Carcinoma, and TBS 2025, a VISTA-blocking immunotherapy, alongside Delta receptor technology for bi-specific ADCs and PDCs.

Brands and product families

  • IFx-2.0 — Lead innate immune response agonist candidate. Source
  • TBS 2025 — VISTA-blocking immunotherapy candidate. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various third-party contract research organizations to conduct and manage its clinical trials and preclinical studies. Source

Business strengths to evaluate

  • Proprietary immuno-oncology technology platform Source

Business risks and research considerations

  • History of operating losses and need for additional capital Source
  • Clinical trial failure or delays Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

HURA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.10
Market capitalization:
133.73M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -30.63M
Free cash flow:
USD -27.71M
Cash:
USD 995.98K
Total debt:
USD 407.02K
EPS:
USD -0.54

What stands out

  • Free cash flow is USD -27.71M, negative for the stored period.
  • The balance sheet shows USD 995.98K of cash versus USD 407.02K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 588.95K using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for HURA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can HURA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is HURA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for HURA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of HURA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research HURA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.